ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026
[Regulatory mechanisms of post-translational modifications in inflammasome signaling: a review].
Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammasomes are central platforms of innate immunity that sense pathogenic and damage-associated signals and drive the maturation of proinflammatory cytokines as well as pyroptotic cell death. Their aberrant activation contributes to a wide range of pathological conditions, including inflammatory, autoimmune, metabolic, and neurological diseases. Recent studies have uncovered a dynamic regulatory network of post-translational modifications (PTMs) that governs the priming, assembly, activation, and degradation of inflammasome signaling. Ubiquitination and deubiquitination primarily control the stability, complex assembly, and degradation of inflammasome components. Phosphorylation and dephosphorylation regulate NLRP3 conformational switching, its interaction with NIMA-related kinase 7, and ASC speck formation through kinase-phosphatase crosstalk, while also modulating NLRC4 and Pyrin inflammasome activation. Acetylation and deacetylation, SUMOylation and deSUMOylation affect inflammasome assembly, protein degradation, and pyroptotic execution in a site- or isoform-specific manner. Collectively, these PTM networks determine the maturation and release of IL-1β and IL-18, as well as the intensity of gasdermin D-mediated pyroptosis. This review summarizes the major types of PTMs, their regulatory mechanisms, and the disease-related advances involving key inflammasome components. It also discusses therapeutic strategies and translational challenges associated with targeting these modification networks, with the aim of providing a reference for mechanistic studies and precision interventions in inflammation-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.